How strong is the evidence for stem-cell therapy in Peripheral Neuropathy?
ClinicalTrials.gov registrations alone cannot establish how strong the evidence is. Registry activity is active but still early, with limited late-phase registration: the registry holds 50 records, 14 completed, 2 at Phase 3 or 4, and 8 stopped early (16%). MSC-specific work accounts for 18 of those records. These counts describe research activity and maturity, not benefit, safety or certainty. Snapshot 2026-08-29.
What counts as a real result in Peripheral Neuropathy
Convincing evidence pairs objective nerve-conduction or intraepidermal nerve-fibre density measures with validated symptom scores, against a control, over six to twelve months. Pain scores alone in an unblinded study are among the softest endpoints in medicine.
What we can say from registrations alone
- Volume: 50 registered studies since 2005.
- Maturity: 2 confirmatory-phase records.
- Delivery: 14 completed; 8 terminated, withdrawn or suspended.
- Scale: median planned enrolment 42 participants, largest 5,000.
The completed studies
Completed does not mean published, and published does not mean positive. These are the finished records — the starting point for checking whether results ever appeared.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT00278629 — Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Completed | 80 | Northwestern University | 2005-02-21 |
| NCT01402284 — Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients | Phase 2 | Completed | 45 | National Cancer Institute (NCI) | 2011-07-21 |
| NCT01065337 — Induced Wound Healing by Application of Expanded Bone Marrow Stem Cells in Diabetic Patients With Critical Limb Ischemia | Phase 2 | Completed | 30 | Ruhr University of Bochum | 2005-08 |
| NCT00411619 — Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex | Phase 1, Phase 2 | Completed | 28 | Children's Hospital Medical Center, Cincinnati | 2007-01 |
| NCT00949325 — Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma | Phase 1, Phase 2 | Completed | 24 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2009-09 |
| NCT00665145 — Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509 | Phase 2 | Completed | 23 | Sangamo Therapeutics | 2008-01 |
What registrations cannot tell you
Whether results were positive. Whether they were published at all — a large share of registered studies never report outcomes, which biases what the literature appears to show. And whether the product a commercial clinic sells resembles the product studied: cell source, dose, processing and delivery route vary enormously between a registered protocol and an off-protocol injection.
How to use this when someone is selling you a treatment
Ask which specific registered study supports the offer, then compare its intervention description with your quote. If the answer is a general gesture at "Peripheral Neuropathy research", you are being sold the field's activity rather than evidence about the product. The Provider Question Builder turns that gap into questions.
Frequently asked
How strong is the evidence for stem-cell therapy in Peripheral Neuropathy?
ClinicalTrials.gov registrations alone cannot establish how strong the evidence is. Registry activity is active but still early, with limited late-phase registration: 50 registered records, 2 at Phase 3/4 and 8 stopped early (2026-08-29).
Has any stem-cell product been approved for this condition?
That has to be checked per product with the regulator that governs where you would be treated. A clinic's own claim of approval is not verification.
Why do clinics cite hundreds of studies?
Because counting registrations is easy and sounds authoritative. The number that matters is how many controlled studies reported a clinically meaningful outcome for the product being sold.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
More on this condition
- Peripheral Neuropathy: cell-therapy evidence and registered trials
- How much does stem cell therapy for Peripheral Neuropathy cost? (2026)
- Peripheral Neuropathy stem cell therapy — your questions answered (2026)
- Peripheral Neuropathy: cell-therapy evidence by therapy class
- MSC vs PRP for Peripheral Neuropathy: what the registries show